Journal article · 2026 · Open access

Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial

Stefanie Weigel, Hans-Werner Hense, Veronika Weyer‐Elberich, Jörg Czwoydzinski, Thomas Decker, Hiltraud Kajüter, Florian Oesterling, Jasper Heilmann, Andreas Stang, Joachim Kieschke, Susanne Wienbeck, Oliver Stephan and 5 more

The Lancet Oncology, 27(11), 1382–1392 · Published 9 October 2026 · DOI 10.1016/s1470-2045(26)00341-4

Open full textCite this paper

In brief

“Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial” is a 2026 journal article by Stefanie Weigel and 16 co-authors, published in The Lancet Oncology. OpenAlex counts 1 citations as of 17 November 2026, which puts it in the top 9% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at The Lancet Oncology.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
2.83
References
24
Authors
17

Abstract

BACKGROUND: Despite high invasive breast cancer detection rates, the effectiveness of digital breast tomosynthesis screening is still uncertain. We aimed to compare the invasive interval cancer rates in women screened with digital breast tomosynthesis plus synthesised two-dimensional (s2D) mammography with those screened with digital mammography. METHODS: TOSYMA is a multicentre, open-label, parallel-group, randomised, controlled, superiority trial done at 17 screening sites across two federal states in Germany. Women aged 50-70 years were randomly allocated (1:1) to digital breast tomosynthesis plus s2D mammography or digital mammography. The first primary endpoint of TOSYMA (TOSYMA-1) was the detection rate of invasive breast cancer and has been previously reported. The second primary endpoint (TOSYMA-2) was the invasive interval cancer rate, defined as the proportion of women who developed an invasive breast cancer in the 24-month interval after being negative at screening (ie, no ductal carcinoma in situ or invasive breast cancer detection) in TOSYMA-1. The primary endpoint was analysed in all participants with a negative screening result in TOSYMA-1. The cumulative incidence of invasive interval cancers at 12 months in screen-negative women was the prespecified secondary outcome. Suspected interval cancers were identified by data linkage to cancer registries. The study is registered on ClinicalTrials.gov (NCT03377036) and is closed to accrual but follow-up is ongoing. FINDINGS: Between July 5, 2018, and Dec 30, 2020, 99 689 women were enrolled in TOSYMA-1 and 99 558 participants included in the modified full analysis set of TOSYMA-1. The median age was 57 years (IQR 53-62) in the TOSYMA-2 modified full analysis set and all participants were female. 49 299 (99·1%) of 49 762 women assigned digital breast tomosynthesis plus s2D mammography screened negative in TOSYMA-1, as were 49 456 (99·3%) of 49 796 women assigned digital mammography who had evaluable data and were included in the TOSYMA-2 modified full analysis set. Invasive interval cancers were detected in 70 of 49 299 women in the digital breast tomosynthesis plus s2D mammography group (invasive interval rate 14·2 cases per 10 000 women screened with a negative result) and in 92 of 49 456 women in the digital mammography group (18·6 cases per 10 000 women screened with a negative result; adjusted odds ratio [OR] 0·76 [95% CI 0·55-1·06]; p=0·11). Invasive interval cancers were detected within 12 months in 22 women in the digital breast tomosynthesis plus s2D mammography group (4·5 cases per 10 000 women screened with a negative result) and in 31 women in the digital mammography group (6·3 cases per 10 000 women screened with a negative result…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Weigel, S., Hense, H.-W., Weyer‐Elberich, V., Czwoydzinski, J., Decker, T., Kajüter, H., Oesterling, F., Heilmann, J., Stang, A., Kieschke, J., Wienbeck, S., Stephan, O., Baier, S., Krischke, M., Sommer, A., Gerß, J., & Heindel, W. L. (2026). Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial. The Lancet Oncology, 27(11), 1382–1392. https://doi.org/10.1016/s1470-2045(26)00341-4

MLA 9

Weigel, Stefanie, et al. “Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial.” The Lancet Oncology, vol. 27, no. 11, 2026, pp. 1382–1392. https://doi.org/10.1016/s1470-2045(26)00341-4.

Chicago

Weigel, Stefanie, Hans-Werner Hense, Veronika Weyer‐Elberich, Jörg Czwoydzinski, Thomas Decker, Hiltraud Kajüter, Florian Oesterling, et al. 2026. “Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial.” The Lancet Oncology 27 (11): 1382–1392. https://doi.org/10.1016/s1470-2045(26)00341-4.

Harvard

Weigel, S. et al. (2026) ‘Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial’, The Lancet Oncology, 27(11), pp. 1382–1392. doi:10.1016/s1470-2045(26)00341-4.

IEEE

S. Weigel et al., “Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial,” The Lancet Oncology, vol. 27, no. 11, pp. 1382–1392, 2026, doi: 10.1016/s1470-2045(26)00341-4.

BibTeX

@article{weigel2026invasive,
  title     = {{Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial}},
  author    = {Weigel, Stefanie and Hense, Hans-Werner and Weyer‐Elberich, Veronika and Czwoydzinski, Jörg and Decker, Thomas and Kajüter, Hiltraud and Oesterling, Florian and Heilmann, Jasper and Stang, Andreas and Kieschke, Joachim and Wienbeck, Susanne and Stephan, Oliver and Baier, Sonja and Krischke, Miriam and Sommer, Alexander and Gerß, Joachim and Heindel, Walter Leonhard},
  journal   = {The Lancet Oncology},
  year      = {2026},
  volume    = {27},
  number    = {11},
  pages     = {1382--1392},
  doi       = {10.1016/s1470-2045(26)00341-4},
  url       = {https://doi.org/10.1016/s1470-2045(26)00341-4}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Digital Radiography and Breast Imaging

  • digital breast tomosynthesis
  • digital mammography
  • breast cancer screening
  • breast cancer detection
  • cancer registry linkage

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Weigel, S., Hense, H.-W., Weyer‐Elberich, V., Czwoydzinski, J., Decker, T., Kajüter, H., Oesterling, F., Heilmann, J., Stang, A., Kieschke, J., Wienbeck, S., Stephan, O., Baier, S., Krischke, M., Sommer, A., Gerß, J., & Heindel, W. L. (2026). Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial. The Lancet Oncology, 27(11), 1382–1392. https://doi.org/10.1016/s1470-2045(26)00341-4

How many times has this paper been cited?

1 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Lancet Oncology: sign in and open the full text from this page.

Who wrote this paper?

Stefanie Weigel, Hans-Werner Hense, Veronika Weyer‐Elberich, Jörg Czwoydzinski, Thomas Decker, Hiltraud Kajüter, Florian Oesterling, Jasper Heilmann, Andreas Stang, Joachim Kieschke, Susanne Wienbeck, Oliver Stephan and 5 more.

What is the DOI of this paper?

10.1016/s1470-2045(26)00341-4, permanently at https://doi.org/10.1016/s1470-2045(26)00341-4. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.